Craft

Guerbet

Stock Price

€33.3

2024-10-29

Market Capitalization

€421.4 M

2024-08-26

Revenue

€785.7 M

FY, 2023

Guerbet Summary

Company Summary

Overview
Guerbet is a human-scale company that aims to become a new global leader in medical imaging. Pioneer in contrast media with 90 years' experience, Guerbet is the only pharmaceutical group dedicated to medical imaging worldwide, with a presence in almost 80 countries via a network of subsidiaries and distributors. The company offers a comprehensive range of CT scan, Cath Lab, Magnetic Resonance Imaging (MRI) and Interventional Radiology and Theranostics (IRT) products, along with a range of injectors and related medical devices to improve patients' diagnosis, prognosis and quality of life. Advancing in innovation solutions, the diagnosis of major diseases (cardiovascular diseases, cancers, diseases of the central nervous system) and interventional radiology while reconciling efficacy and cost containment, are at the heart of Guerbet's mission.
Type
Public
Status
Active
Founded
1926
HQ
Villepinte, FR | view all locations
Website
http://www.guerbet.com/
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

  • Pierre Desché, Development, Medical & Regulatory Affairs VP

    • David Hale, Chief Commercial Officer Diagnostic Imaging

      • Claire Corot, Research, Innovation & Business Development VP

        LocationsView all

        36 locations detected

        • Villepinte, Île-de-France HQ

          France

          15 Rue des Vanesses

        • Cincinnati, OH

          United States

          2111 E Galbraith Rd

        • Princeton, NJ

          United States

          821 Alexander Rd #204

        • Raleigh, NC

          United States

          8800 Durant Rd

        • Lane Cove West, NSW

          Australia

          Level 2/166 Epping Rd

        • Wien, Wien

          Austria

          Handelskai 94-96

        and 30 others

        Guerbet Financials

        Summary Financials

        Revenue (FY, 2023)
        €785.7M
        Gross profit (FY, 2023)
        €620.3M
        Net income (FY, 2023)
        €22.2M
        Cash (FY, 2023)
        €51.3M
        EBIT (FY, 2023)
        €39.2M
        Enterprise value
        $757.1M

        Footer menu